What was the biggest price drop for GILD?

The deepest fall in our weekly price history since October 2006 was 52.36%, from a high in the week of June 15, 2015 to a low in the week of December 21, 2020. The price regained that high in the week of October 13, 2025.

Which month has historically been best for GILD?

Since 2015, January has had the highest average return for GILD (+3.64%, up in 6 of 12 years) and December the lowest (-2.62%, up in 3 of 11 years). Past seasonal patterns do not predict future returns.

stock · yahoo

GILD

$156.19

▼ 1.18 (-0.75%)

Last close · Oct 16

Below: live stock price for GILD (GILD), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.

GILD (GILD) is a Healthcare company based in United States. Operating in Drug Manufacturers - General, it employs about 17,000 people. Over the past year GILD traded between 114.02 and 160.51 USD. It currently yields 2.10% in dividends.

Day

-0.75%

-1.18

Week

+3.32%

+5.02

Month

+4.05%

+6.08

Year

—

Prev close: $157.37
Volume (24h): —
Market cap: —
Currency: USD

Score

43/ 100 · Weak

Coverage: 7/7

Value32
Quality44
Momentum51
Growth43
Risk49
Dividend52
Liquidity28

Composite of public market data. Informational only — not investment advice.

Trend projection

Where the recent trend points if it continues.

UptrendFit 69%Pace +0.25% per bar

+5 bars+20 bars+60 bars+120 bars

+5 bars: 157.7448
+20 bars: 159.9155
+60 bars: 160.7632
+120 bars: 160.7944

Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.0297 USD.

Interpretation

Composite signals look weak. Strength: dividend with weakness: balance-sheet liquidity. Price sits near the upper third of the recent range, trend is sloping upward.

Descriptive observation — not investment advice.

Score breakdown

Raw values behind each pillar so you can see what the composite is reading.

Value
32/100
Value looks weak — driven by P/B (16.39).
P/E:15.71P/B:16.39PEG:2.32
Quality
44/100
Quality looks weak — driven by Gross margin (79.60%).
ROE:-20.68%ROA:14.09%Profit margin:-10.64%Gross margin:79.60%
Momentum
51/100
Momentum looks mixed — driven by 52w change (26.87%).
52w change:26.87%
Growth
43/100
Growth looks weak — driven by Revenue growth (10.20%).
Revenue growth:10.20%
Risk
49/100
Risk looks mixed — driven by Debt / equity (223.47).
Beta:0.33Debt / equity:223.47Short interest:1.76%
Dividend
52/100
Dividend looks mixed — driven by Payout ratio (43.46%).
Dividend yield:2.10%Payout ratio:43.46%
Liquidity
28/100
Liquidity looks fragile — driven by Current ratio (1.27).
Current ratio:1.27Quick ratio:0.9

Derived from public market data — informational, not investment advice.

Price report

How this asset has actually moved over the last 250 days.

Position in range91%

114.02 low160.51 high

Where the price sits between the window low and high.

Volatility (annualised): 26.6%
Max drawdown: -22.0%
Below period high: -2.7%
Best day: +5.82%
Worst day: -3.72%
Up days: 49%
Current streak: 1 down
Typical day swing: 2.5%
Volume vs average: -4%

Descriptive statistics over past prices — not a forecast and not investment advice.

Reference levels

Fibonacci retracements and extensions across the recent range.

60 bars

Reference only — not investment advice.

These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.

Next level above

169.2766 USD+8.38%

Fib +27.2% extension

Next level below

152.9037 USD-2.10%

Fib 23.6% retracement

Levels derived from: 160.51 high → 128.28 low · 60 bars

Resistance
Fib +161.8% extension
not reached
212.6581 USD
+36.15% from current
Resistance
Fib +100% extension
not reached
192.74 USD
+23.40% from current
Resistance
Fib +61.8% extension
not reached
180.4281 USD
+15.52% from current
Resistance
Fib +27.2% extension
not reached
169.2766 USD
+8.38% from current
Current
156.19 USD
Support
Fib 23.6% retracementNearest
tested 5×
152.9037 USD
-2.10% from current
Support
Fib 38.2% retracement
tested 15×
148.1981 USD
-5.12% from current
Support
Fib 50% midpoint
tested 11×
144.395 USD
-7.55% from current
Support
Fib 61.8% retracement
tested 1×
140.5919 USD
-9.99% from current
Support
Fib 78.6% retracement
tested 5×
135.1772 USD
-13.45% from current
Support
Fib −27.2% extension
not reached
119.5134 USD
-23.48% from current
Support
Fib −61.8% extension
not reached
108.3619 USD
-30.62% from current
Support
Fib −100% extension
not reached
96.05 USD
-38.50% from current

How to read this

We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.

“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.

This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.

Financials

52w high: $160.51
52w low: $114.02
52w change: 26.87%
Day high: $157.51
Day low: $155.62
Forward P/E: 15.71
PEG: 2.32
Price / Book: 16.39
Beta (5Y): 0.33
Enterprise value: 214.95B
EV / Revenue: 7.06
EV / EBITDA: 14.72
EPS (TTM): -$2.65
Forward EPS: $9.94
Dividend yield: 2.10%
Dividend rate: $3.28
Payout ratio: 43.46%
Revenue (TTM): 30.46B
EBITDA: 14.6B
Free cash flow: 9.77B
Total cash: 4.88B
Total debt: 26.25B
Debt / Equity: 223.47
Current ratio: 1.27
Quick ratio: 0.9
Profit margin: -10.64%
Gross margin: 79.60%
Return on assets: 14.09%
Return on equity: -20.68%
Shares outstanding: 1.24B
Float: 1.24B

Sector: HealthcareIndustry: Drug Manufacturers - GeneralHQ: United StatesEmployees: 17Kwww.gilead.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.

Analyst & Risk

Consensus

Buy

Mean rating1.68 / 5

Analysts26

Next earnings2026-10-29

Strong buy 6Buy 16Hold 5Strong sell 1

Analyst price target

$159.85

Mean target · 26 analysts

+2.3%

upside

Low $126.00Now $156.19High $180.00

Beta (vs S&P 500): 0.33; very stable
52-week change: 26.87%
Short % of float: 1.76%
Short ratio (days): 3.7
Debt / Equity: 223.47; very high leverage
Current ratio: 1.27
Quick ratio: 0.9
ROE: -20.68%
ROA: 14.09%
PEG ratio: 2.32; richly valued
EV / Revenue: 7.06
EV / EBITDA: 14.72
Revenue growth: 10.20%
EBITDA: 14.6B
Free cash flow: 9.77B
Total cash: 4.88B
Total debt: 26.25B
Insider holdings: 0.11%
Institutional: 92.07%

Recent rating changes

2026-10-08RBC CapitalSector Perform → Sector Performmain
2026-10-08Cantor FitzgeraldOverweight → Overweightreit
2026-10-07Truist SecuritiesBuy → Buymain
2026-10-07JP MorganOverweight → Overweightmain
2026-10-07Morgan StanleyOverweight → Overweightmain
2026-09-10HSBCBuy → Buymain
2026-08-05RBC CapitalSector Perform → Sector Performmain
2026-08-05Cantor FitzgeraldOverweight → Overweightreit

Financial documents

GILD performance

Change from the closing price at the start of each period to the latest price.

Period	Start price	Change	Per year
1 week$151.17	$151.17	+3.32%
1 month$147.68	$147.68	+5.76%
3 months$136.30	$136.30	+14.59%
6 months$138.55	$138.55	+12.73%
Year to date$122.74	$122.74	+27.25%
1 year$123.11	$123.11	+26.87%
3 years$77.65	$77.65	+101.1%	+26.13%
5 years$67.63	$67.63	+130.9%	+18.21%
10 years$72.75	$72.75	+114.7%	+7.94%
Since Oct 2006$17.05	$17.05	+816.3%	+11.73%

Periods up to a year use daily closes, longer ones weekly closes. “Per year” is the compound annual growth rate.

Price change only; dividends are not included.

GILD all-time high and low

Highest since Oct 2006

$160.51

Oct 15, 2026

2.69% below the high

Lowest since Oct 2006

$15.48

week of Jan 1, 2007

909.0% above the low

52-week range

91%

Low

$114.02

Oct 31, 2025

High

$160.51

Oct 15, 2026

The latest price sits at 91% of this range.

Highs and lows include intraday prices.

GILD risk metrics

Past year of daily closes unless stated otherwise.

Volatility (1 year, annualised): 26.59%; How large price swings have been: the standard deviation of daily returns, scaled up to a year.
Max drawdown (1 year): -22.03%; Feb 11, 2026 → Jun 10, 2026 · Recovered on Oct 15, 2026.; The deepest fall from a previous high to a later low over the past year.
Max drawdown (since Oct 2006): -52.36%; Jun 2015 → Dec 2020 · Recovered in the week of Oct 13, 2025.; The same measure across the whole weekly price history.
Sharpe ratio (risk-free rate 0): 1.03; Average daily return divided by its volatility, annualised: higher means more return for each unit of risk over the past year.
Beta vs S&P 500 (1 year): 0.34; On average, GILD moved 0.34% for each 1% move in the S&P 500 on the same day.

GILD drawdown from peak

How far the price stood below its previous high, based on weekly closes since Oct 2006.

GILD seasonality

Monthly returns by year, from month-end closes: daily data for the past year, weekly closes before that.

GILD seasonality
Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	+16%	+4.9%	-6.4%	-6.1%	+2.7%	-6.0%	+3.1%	+12%	+1.9%	+4.8%*			+27%*
2025	+3.3%	+18%	-2.2%

GILD price history

Yearly open, high, low and close, newest first.

GILD price history
Year	Open	High	Low	Close	Change
2026YTD	$122.49	$160.51	$116.88	$156.19	+27.25%
2025	$93.93	$128.70	$88.57	$122.74	+30.42%
2024	$80.91	$98.90	$62.07	$94.11	+16.17%
2023	$85.08	$88.29	$72.87	$81.01	-5.64%
2022	$72.27	$89.74	$57.17	$85.85	+18.23%

Frequently asked questions about GILD

What is the price of GILD today?

As of October 16, 2026, the price of GILD is $156.19, down 0.75% from the previous close.

What is the all-time high of GILD?

The highest price for GILD in our data, which starts in October 2006, is $160.51, reached on October 15, 2026. At $156.19, the latest price is 2.69% below it.

How much has GILD gained this year?

GILD is up 27.25% so far in 2026: it closed 2025 at $122.74 and is at $156.19 now.

How volatile is GILD?

Calculated from historical closing prices — daily for the past year, weekly before that — and refreshed as new prices arrive. Past performance does not predict future returns. Not investment advice.


Average	+3.6%	-0.5%	-0.2%	-1.8%	-0.1%	+1.9%	+1.2%	+1.1%	-1.3%	+2.0%	+3.4%	-2.6%	+4.0%
Years up	50%	33%	42%	33%	42%	58%	50%	50%	25%	55%	82%	27%	64%

Year	Open	High	Low	Close	Change
2021	$58.67	$74.12	$57.93	$72.61	+24.63%
2020	$65.73	$85.97	$56.56	$58.26	-11.66%
2019	$62.00	$70.50	$60.89	$65.95	+6.58%
2018	$72.19	$89.54	$60.32	$61.88	-13.62%
2017	$72.34	$86.27	$63.76	$71.64	+0.04%
2016	$99.77	$103.10	$70.83	$71.61	-29.23%
2015	$96.07	$123.37	$86.00	$101.19	+7.89%
2014	$74.67	$116.83	$63.50	$93.79	+25.98%
2013	$36.13	$76.11	$35.85	$74.45	+105.7%
2012	$20.73	$38.56	$20.67	$36.19	+76.84%
2011	$18.32	$21.75	$17.23	$20.47	+12.94%
2010	$21.69	$24.75	$15.86	$18.12	-16.25%
2009	$25.35	$26.64	$20.31	$21.64	-13.48%
2008	$23.00	$28.82	$17.80	$25.00	+7.94%
2007	$16.32	$23.95	$15.48	$23.17	+42.71%
2006from October	$17.17	$17.50	$15.78	$16.23	—

Month	Close	Change
September 2026	$149.05	+1.85%
August 2026	$146.34	+12.39%
July 2026	$130.21	+3.06%
June 2026	$126.34	-6.02%
May 2026	$134.43	+2.74%
April 2026	$130.84	-6.12%

Month	Close	Change
March 2026	$139.37	-6.43%
February 2026	$148.95	+4.93%
January 2026	$141.95	+15.65%
December 2025	$122.74	-2.46%
November 2025	$125.84	+5.05%
October 2025	$119.79	+6.86%

GILD

Financials

Analyst & Risk

Recent rating changes

Financial documents

GILD performance

GILD all-time high and low

52-week range

GILD risk metrics

GILD drawdown from peak

GILD seasonality

GILD price history

Frequently asked questions about GILD

What is the price of GILD today?

What is the all-time high of GILD?

How much has GILD gained this year?

How volatile is GILD?

Recent news

Learn the terms

Live discussion

GILD performance

GILD all-time high and low

52-week range

GILD risk metrics

GILD drawdown from peak

GILD seasonality

GILD price history

Frequently asked questions about GILD

What is the price of GILD today?

What is the all-time high of GILD?

How much has GILD gained this year?

How volatile is GILD?

GILD month-end closes

What was the biggest price drop for GILD?

Which month has historically been best for GILD?